Butterfly Network logo
Butterfly Network BFLY
$ 7.52 2.17%
report update icon

Quarterly report 2026-Q2
added 07-30-2026

Butterfly Network Financial Ratios 2025-2011 | BFLY

Brief overview of Butterfly Network's multiples and efficiency

The review covers five available annual periods spanning 2021 to 2025.

Key multiples at the end of the period are P/S 9.7x (median 9.34x), P/B 4.83x (median 2.6x). Multiples are on average 44.9% above their own medians. A substantial share of positive expectations may already be priced in.

The latest available business-quality ratios are ROE -39.3%, ROA -26%, ROCE -44.1%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.

PEG is 0.32x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.

The time from paying for inputs to receiving cash rose from 211.4 days to 519.8 days. Cash turnover slowed.

What the ratios show

Butterfly Network's valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.

Annual Financial Ratios Butterfly Network

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-12.3 -10.6 -1.9 -2.3 -35.9 -0.7 - - - - - - - - -

P/S

9.7 9.3 3.8 5.3 18.6 2.6 - - - - - - - - -

EPS

-0.3 -0.3 -0.7 -0.8 -0.2 -26.9 -17.1 - - - - - - - -

EV (Enterprise Value)

897 M 765 M 202 M 313 M 860 M 59.7 M -90 M -215 M - - - - - - -

EBITDA per Share

-0.32 -0.31 -0.67 -0.94 -1.1 -26.5 - - - - - - - - -

EV/EBITDA

-11.2 -11.7 -1.5 -1.7 -3.9 - - - - - - - - - -

PEG

0.32 - - - - - - - - - - - - - -

P/B

4.8 4.5 1.1 1.2 2.6 - - - - - - - - - -

P/CF

-74.5 -18.4 -2.6 -2.3 -6.1 -1.5 - - - - - - - - -

ROE %

-39.32 -42.94 -60.76 -51.86 -7.24 44.97 - - - - - - - - -

ROA %

-25.99 -28.31 -43.94 -40.41 -5.67 - - - - - - - - - -

ROCE %

-44.09 -44.07 -66.17 -59.33 -43.05 44.65 - - - - - - - - -

Current Ratio

2.9 2.9 3.6 4.5 4.6 - - - - - - - - - -

DSO

88.9 76.1 77.8 66.2 51.6 22.7 - - - - - - - - -

DIO

465.0 789.9 494.9 517.5 248.8 43.8 - - - - - - - - -

DPO

34.1 51.3 45.8 70.0 89.0 27.8 - - - - - - - - -

Operating Cycle

553.9 866.0 572.7 583.7 300.4 66.5 - - - - - - - - -

Cash Conversion Cycle

519.8 814.7 526.9 513.7 211.4 38.7 - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Butterfly Network

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.05 -0.05 -0.13 -0.06 -0.06 -0.08 -0.07 -0.1 -0.13 -0.14 -0.17 - -0.27 -0.18 -0.22 - -0.07 -0.02 -0.01 - -15.2 -3.85 -4.07 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.05 -0.05 -0.14 -0.06 -0.08 - - - - - -0.16 - -0.21 -0.24 -0.24 - -0.28 -0.19 -0.5 - -15 -3.73 -4.05 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-36.05 -35.07 -37.74 -29.16 -33.89 -38.69 -39.71 -42.95 -48.21 -46.84 -47.29 -35.97 -38.97 -23.70 -14.60 -3.82 21.65 31.08 38.47 38.63 25.48 6.42 6.73 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-25.13 -24.95 -26.90 -20.93 -24.17 -27.97 -29.46 -32.49 -37.19 -37.31 -31.78 -22.99 -23.46 -11.11 -11.22 -2.91 -65.55 -79.01 -95.09 -94.98 -62.65 -15.79 -16.55 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-38.62 -39.11 -41.34 -32.97 -37.15 -42.09 -43.87 -46.83 -49.14 -49.02 -49.76 -37.93 -50.56 -45.38 -45.17 -33.17 -7.80 11.20 26.19 38.52 25.37 6.37 6.77 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

3.0 3.0 3.4 3.9 4.0 3.2 3.5 3.5 4.3 4.2 4.5 4.5 4.5 - 4.4 4.6 4.5 3.4 3.1 1.0 1.0 1.0 1.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

83.6 85.3 103.9 86.7 87.1 81.5 63.8 71.2 93.0 77.1 83.0 - 27.5 31.0 73.3 - 54.1 36.0 40.3 - 51.8 44.5 30.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

576.7 672.5 237.0 742.6 829.2 807.8 762.0 1041.8 1366.3 942.2 924.2 - 304.9 255.2 533.7 - 163.5 457.1 468.8 - 29.7 202.5 123.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

31.0 33.9 12.0 30.1 34.5 44.7 52.9 86.0 124.5 83.3 90.3 - 14.1 14.2 53.5 - 23.8 57.9 164.0 - 18.9 128.7 78.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - 340.9 829.3 916.3 889.3 825.8 1113.0 1459.2 1019.4 1007.2 - 332.4 286.3 607.0 - 217.7 493.1 509.1 - 81.5 247.0 154.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - 328.9 799.2 881.8 844.6 772.9 1027.0 1334.7 936.1 916.9 - 318.2 272.1 553.5 - 193.9 435.2 345.1 - 62.6 118.3 75.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Butterfly Network, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Sintx Technologies Sintx Technologies
SINT
$ 1.74 6.75 % $ 4.83 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 27.87 0.16 % $ 24.2 B britainBritain
Stryker Corporation Stryker Corporation
SYK
$ 276.43 0.68 % $ 106 B usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 19.88 0.4 % $ 1.35 B usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 3.16 0.94 % $ 51.6 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 8.79 0.78 % $ 342 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 18.49 0.03 % $ 765 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Vivos Therapeutics Vivos Therapeutics
VVOS
$ 0.18 6.76 % $ 1.85 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.83 1.05 % $ 39 M usaUSA
Beyond Air Beyond Air
XAIR
$ 3.38 0.93 % $ 28.1 B usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 94.22 0.69 % $ 18.7 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.23 0.71 % $ 600 M israelIsrael
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 6.81 1.32 % $ 206 M canadaCanada
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 21.73 0.09 % $ 497 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 105.52 0.03 % $ 184 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 1.81 1.09 % $ 1.22 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 6.19 1.09 % $ 837 M usaUSA
Align Technology Align Technology
ALGN
$ 153.49 0.03 % $ 11.1 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.05 0.33 % $ 125 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.26 0.37 % $ 31.9 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 9.19 1.29 % $ 1.38 B usaUSA
AxoGen AxoGen
AXGN
$ 46.69 2.51 % $ 2.15 B usaUSA